Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Instagram Outage Disrupts Thousands of U.S. Users 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
VANCOUVER, British Columbia, Aug. 02, 2017 -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Mark DiPaolo to its board of directors, effective immediately.
Jason Aryeh, chairman of the board of directors, said, “Mark brings to Novelion’s board a keen understanding of the biotech industry, a shared vision for maximizing shareholder value and a sharp focus on capital allocation. We look forward to his insights as we seek to build Novelion into a leading rare disease-focused company.”
Mr. DiPaolo is a partner and the General Counsel of Sarissa Capital Management LP, a registered investment advisor, since 2013. Sarissa Capital focuses on improving the strategies of companies to enhance shareholder value. From 2005 to 2013, Mr. DiPaolo served as a senior member of Icahn Capital’s management team, working on investing aspects of Carl Icahn’s activist strategy. Prior to working with Icahn Capital, Mr. DiPaolo was an attorney with Willkie Farr & Gallagher LLP. Mr. DiPaolo received his B.A. degree from Fordham University and his J.D. degree from Georgetown University Law Center.
Mr. Aryeh added, “As previously announced, John Orloff, M.D., is now officially a member of our board. We are thrilled to benefit from his strategic guidance as the Company executes metreleptin life-cycle management and R&D plans.”
The company also announced that Geoffrey Cox, Ph.D., and Jorge Plutzky, M.D., stepped down from the Novelion Board of Directors as of July 31, 2017 and August 1, 2017, respectively.
“We thank Jorge and Geoff for their many contributions as we formed and created the strategic direction for Novelion,” continued Mr. Aryeh.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the potential treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
CONTACT: Amanda Murphy, Director, Investor & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
